Since the introduction of prostate-specific antigen (PSA) testing in 1986, the incidence of prostate cancer in the US and Europe spiked and subsequently declined due to issues like false positives, overdiagnosis, and overtreatment, affecting up to 20–50% of diagnosed men who might never have developed symptoms [11]. The gene discussed is KLK3; the disease is prostate carcinoma.